Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Apache Indian who wrote (312)	4/6/1998 8:30:00 AM
From: BRAVEHEART	Read Replies (1) of 1494

Hi Apache Indian, Over 1 million additional shares were issued to existing shareholders in raising a little over 550,000 for two months of operations. There is now about 7.5 million shares outstanding. The options have not been exercised these exist solely for incentives for existing employees. I don't see how you can overlook the fact that current investors have so much confidence in the eventual likelihood of a deal with big pharma that they are willing to risk their own funds rather than seek expensive dollars elsewhere. You will be able to access the filing for the new shares within the 45 day period allowed for such filing. Help me out here, don't you think these shareholders who just received 1 million additional shares at rock bottom prices know something. I will definately continue to accumulate based on this recent development. PS: Forget about so little dilution for these products will easily move so few shares with positive announcments. I'd rather have this than convertables issued where the price is hammered ( shorted )down. No if you are long here you should be interested in this development. How can you not be. PSS: Yes mixed results that is why they are conducting an exclusive P-2 trial for diabetic nuropathies, because the earlier trials were significant. Keep in mind small biotech's rarely do several P-2 tests to determine all their endpoints clearly however the major Pharma's do. NTII is showing the niche capabilities of it's clinical only approach to bringing a drug to market. Once this company gets back on it's feet I really like it's prospects long term. Call me crazy but my guess is in a few years this company will be alive and highly successful. LONE WOLF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next